Highlights
- •Some variant RARA rearrangements are insensitive to all-trans retinoic acid (ATRA) therapy.
- •We report a rarely described STAT5B/RARA fusion that was insensitive to ATRA therapy.
Abstract
The detection of PML/RARA or variant RARA rearrangements is critical for the diagnosis and treatment of patients with newly
diagnosed acute promyelocytic leukemia (APL). While most cases of APL harboring the
PML/RARA fusion respond to all-trans retinoic acid (ATRA), some variant RARA rearrangements are ATRA insensitive. Herein, we report a 27-year-old male with newly
diagnosed, rapidly progressive APL and a rarely described STAT5B/RARA fusion with known resistance to ATRA therapy. While the PML/RARA dual-color dual-fusion fluorescence in situ hybridization (FISH) probe study was negative, the RARA break-apart probe study revealed an atypical RARA rearrangement in 95% of nuclei. A next generation sequencing assay, mate-pair sequencing,
was subsequently performed to further characterize the RARA rearrangement and identified the RARA gene fusion partner STAT5B.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cancer GeneticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Acute myeloid leukaemia with recurrent genetic abnormalities.in: Swerdlow S.H. Campo E. Harris N.L. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer (IARC), Lyon, France2017: 130-149
- Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.Blood. 1999; 93: 3167-3215
- Acute promyelocytic leukemia: a review and discussion of variant translocations.Arch Pathol Lab Med. 2015; 139: 1308-1313
- Diagnosis of variant RARA translocation using standard dual-color dual-fusion PML/RARA FISH probes: an illustrative report.Hematol Oncol Stem Cell Ther. 2019; 12: 50-53
- BIMA V3: an aligner customized for mate pair library sequencing.Bioinformatics. 2014; 30: 1627-1629
- SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq).Cancer Genet. 2018; 221: 1-18
- Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.Eur J Haematol. 2019; 102: 87-96
- Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.Front Oncol. 2011; 1: 35
- All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.Leukemia. 2013; 27: 1606-1610
- Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance by a custom next-generation sequencing assay.Cold Spring Harb Mol Case Stud. 2015; 1a000307
- Clinical characteristics of acute promyelocytic leukemia with the STAT5B/RARA fusion gene.Blood Cells Mol Dis. 2018; 69: 71-73
- STAT5b-RARa-positive acute myeloid leukemia: diagnostic and therapeutic challenges of a rare AML subtype.Leuk Res. 2019; 78: 21-23
- Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.Leuk lymphoma. 2018; 59: 763-765
- Acute promyelocytic leukemia with a STAT5B-RARα fusion transcript defined by arrary-CGH, FISH, and RT-PCR.Cancer Genet. 2012; 205: 327-331
- Mechanisms of action and resistance to all-trans- retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.Int J Hematol. 2013; : 717-725
Article Info
Publication History
Published online: June 12, 2019
Accepted:
June 11,
2019
Received in revised form:
June 8,
2019
Received:
May 1,
2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.